Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 8,095 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SAMe Clear all
Completed Phase 1 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

NCT06107803
View directory record Official record
Conditions
Negative Symptoms in Schizophrenia
Interventions
Roluperidone 64 mg, Olanzapine 10 MG
Drug
Lead sponsor
Minerva Neurosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Garden Grove, California • Gaithersburg, Maryland • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 21, 2026, 6:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

NCT01784861
View directory record Official record
Conditions
Adenocarcinoma, Pancreatic Neoplasms
Interventions
X-82, Everolimus
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 21, 2026, 6:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Percutaneous Nephrolithotomy Versus Extracorporeal Shock Wave Lithotripsy

NCT00873054
View directory record Official record
Conditions
Kidney Stones
Interventions
Not listed
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 21, 2026, 6:54 AM EDT
Recruiting Phase 2 Interventional

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07643766
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ENV-294, Placebo
Drug · Other
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Northridge, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

NCT02401256
View directory record Official record
Conditions
Healthy
Interventions
Efavirenz, Bupropion, Rosuvastatin, Montelukast
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 21, 2026, 6:54 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy and Sustainability of a Carepartner-Integrated Telerehabilitation Program for Persons With Stroke

NCT06655402
View directory record Official record
Conditions
Stroke, Caregiver Burden
Interventions
CARE-CITE, Attention Control Group, Actigraph GT3X+
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 21, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study

NCT02642029
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I
Interventions
Excitatory TMS, Inhibitory TMS, Sham TMS
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Belmont, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 21, 2026, 6:54 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Endometriosis and Migraine

NCT06785129
View directory record Official record
Conditions
Migraine, Endometriosis
Interventions
Thermal stimuli, Pressure stimuli, Pain ratings, Conditioned pain modulation (CPM) response, Hormonal assessment
Device · Behavioral · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Results available

Managing Alcoholism in People Who Do Not Respond to Naltrexone

NCT00115037
View directory record Official record
Conditions
Alcoholism
Interventions
Naltrexone, placebo, Medication Management (MM), Combined Behavioral Intervention (CBI), Telephone Counseling
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 21, 2026, 6:54 AM EDT
Completed Not applicable Interventional

Remediation of the Non-Paretic Arm in Stroke

NCT03062930
View directory record Official record
Conditions
Stroke
Interventions
Track 1, Track 2
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 21, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

NCT01154101
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
St Louis, Missouri • New York, New York • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 21, 2026, 6:54 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow

NCT01085981
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%, Topical study cream, GRAS cream
Drug
Lead sponsor
East Suburban Ob Gyn
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2010 · Synced Oct 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

NCT00979875
View directory record Official record
Conditions
Healthy
Interventions
Recombinant human hyaluronidase PH20 (rHuPH20), Insulin lispro, Insulin glulisine, Insulin aspart
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 21, 2026, 6:54 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening

NCT04904757
View directory record Official record
Conditions
Mammographic Breast Density, Mammography
Interventions
Contrast-enhanced spectral mammography (CESM)
Device
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 21, 2026, 6:54 AM EDT
Not listed Not applicable Interventional

Dual Joint Visual Feedback Gait Retraining in Pediatric Hemiplegic Cerebral Palsy

NCT05011201
View directory record Official record
Conditions
Hemiplegic Cerebral Palsy
Interventions
Dual Joint Visual Feedback without Scoring, Dual Joint Visual Feedback with Scoring
Device
Lead sponsor
Kessler Foundation
Other
Eligibility
7 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 21, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation of a CBD Supplement's Impact on Sleep, Stress, and Focus

NCT05518019
View directory record Official record
Conditions
Anxiety, Fear, Stress, Low Mood, Sleep
Interventions
The Daily Supplement
Dietary Supplement
Lead sponsor
Prima CBD
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 21, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

NCT01382719
View directory record Official record
Conditions
Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Interventions
bremelanotide
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
21 Years and older · Female only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
65
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 21, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome

NCT04540887
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Pulsed Electromagnetic Field (PEMF) Therapy
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 21, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia

NCT01891721
View directory record Official record
Conditions
Schizophrenia
Interventions
Brain Fitness Program (BFP), Cognitive Package (Cogpack), Commercial Computer Games (Sporcle)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
25 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Los Angeles, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 21, 2026, 6:54 AM EDT
Not listed Not applicable Interventional

Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform

NCT06344416
View directory record Official record
Conditions
Any Solid Oral Medication
Interventions
Use of ReX to dispense and monitor solid oral medication therapy.
Device
Lead sponsor
Dosentrx Ltd.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Minneapolis, Minnesota • Austin, Texas • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 21, 2026, 6:54 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

NCT02425904
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Clofarabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 21, 2026, 6:54 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma

NCT06614855
View directory record Official record
Conditions
Glioblastoma, Glioblastoma (GBM), Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Gliosarcoma, Adult, Gliosarcoma of Brain
Interventions
C134
Drug
Lead sponsor
James Markert, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 6:54 AM EDT
Withdrawn Not applicable Interventional

Memory-Updating Technique to Reduce Food Craving and High Calorie Food Intake Among Individuals With Overweight/Obesity

NCT04077385
View directory record Official record
Conditions
Overweight, Obesity, Craving, Eating Behavior
Interventions
Retrieval-extinction (R-E) Training, Extinction Training
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 21, 2026, 6:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

NCT02362035
View directory record Official record
Conditions
Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia
Interventions
Acalabrutinib, Pembrolizumab
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 6:54 AM EDT